However, compared to the isotype treatment, treatments with systemic anti‐IFNAR1 and anti‐IL‐1β antibodies abrogated anti‐tumor effects, as evidenced by significantly increased tumor size and tumor weight of mice bearing the Arf1‐ablated tumor cells (Figure 6a,b). Here, ARF1 is linked to neoplasm.